ASCO: Loxo Steals the Show, and Consistent Data from Bluebird
Research - ASCO is in full swing, which we covered in our last two webinars (April / May). Some of these are playing out today, most notably … Continue Reading
PremiumSearch Results for gene therapy
Migraine Space Consolidation Hasn’t Slowed
Research - Sure enough, Sage’s (SAGE) phase 3 STATUS data have leaked into the third quarter. Our suggestion for some August hedge protection may still work, as … Continue Reading
Premium
The Well-Worn Path of ERTs
Long Ideas - Last July, Ultragenyx Pharmaceutical (RARE) released positive results from a phase 3 study of its enzyme replacement therapy rhGUS (recombinant human beta-glucuronidase) in the lysosomal … Continue Reading
Read now
Bluebird Pulls Back The Curtain On First CAR-T Results
Research - Bluebird bio (BLUE) posted the first human results for its anti-BCMA CAR-T candidate bb2121 last evening. This is a novel indication for CAR-T products, and … Continue Reading
Premium
Don’t Misunderstand Cascadian: TWO Events That Matter This December
Research - For a refresher, Cascadian develops tucatinib (ONT-380), an EGFR-avoiding HER2 inhibitor in mid-stage development for metastatic HER2-positive breast cancer. After two open-label studies in late-stage mBC, a shake-up in the executive suite, and a recent financing, CASC has moved forward with the 180-patient phase 2 HER2CLIMB study, hoping to pivot this study to registration status (with input from the FDA) by the end of the year.
Premium
Medical Conferences Loom: PropThink’s October Webinar
Insights - A recording of our October Healthcare Huddle is now available. Unfortunately, SOMEONE forgot to record the actual webinar last night, so we re-recorded it this … Continue Reading
PremiumASCO 2016 Trade Updates
Research - Ariad Pharmaceuticals (ARIA) reported Monday morning updated results from the ALTA trial, testing brigatinib in ALK+ non-small cell lung cancer patients who had experienced disease … Continue Reading
Premium